UnitedHealth Group, CVS Health, and Cigna are challenging state-level pharmacy benefit manager (PBM) regulations in federal court, arguing that federal law preempts local oversight. These lawsuits, filed in jurisdictions such as Oklahoma and Arkansas, contest state attempts to regulate pharmacy networks and drug pricing, creating a significant legal conflict between state authority and the Employee Retirement Income Security Act (ERISA).
The Legal Conflict Over PBM Regulation
Major health insurers and PBMs, including UnitedHealth’s OptumRx, CVS Caremark, and Cigna’s Express Scripts, are pushing back against state laws that seek to impose transparency and network requirements on their operations. According to filings in the U.S. District Court for the Western District of Oklahoma, these companies contend that state regulations interfere with the uniform administration of employee benefit plans.
The industry argument centers on the federal Employee Retirement Income Security Act (ERISA). PBMs argue that because they manage prescription drug benefits for self-funded employer plans, their operations should be governed by federal standards rather than a patchwork of state-specific mandates. By suing to block these laws, these firms aim to prevent states from dictating which pharmacies must be included in their networks or how they must structure their reimbursement models.
State-Level PBM Oversight and Precedent
States have increasingly enacted legislation to curb PBM practices, citing concerns over rising drug costs and the exclusion of independent pharmacies from coverage networks. These laws often require PBMs to disclose rebate information, limit "spread pricing"—where a PBM charges a health plan more than it pays the pharmacy—and ensure that patients have access to any pharmacy willing to accept the PBM’s terms.
The legal landscape shifted significantly following the 2020 U.S. Supreme Court ruling in Rutledge v. Pharmaceutical Care Management Association. In that case, the Court held that an Arkansas law regulating PBM reimbursement rates was not preempted by ERISA. The ruling provided states with a framework to regulate the economic aspects of PBM operations. However, industry players are now testing the limits of that precedent, arguing that the specific statutes in states like Oklahoma go beyond mere price regulation and improperly dictate plan administration.
Industry Impact and Regulatory Stakes
The outcome of these challenges will determine the scope of state authority in the healthcare supply chain. PBMs argue that state-imposed administrative burdens increase costs for employers and plan sponsors. Conversely, state regulators and pharmacy advocacy groups maintain that these laws are necessary to prevent anti-competitive behavior that harms local pharmacies and increases consumer out-of-pocket costs.
Key Points of Contention
- ERISA Preemption: The central legal question is whether state PBM laws "relate to" employee benefit plans, which would trigger ERISA preemption.
- Network Access: States are attempting to pass "Any Willing Pharmacy" laws, which force PBMs to include any pharmacy that agrees to the plan’s terms and conditions.
- Transparency Mandates: Requirements for PBMs to pass through 100% of rebates to plan sponsors or consumers are a primary target of industry opposition.
As these cases move through federal courts, the industry faces a fragmented regulatory environment. If courts uphold the state laws, PBMs will be forced to adjust their operational models to comply with differing requirements across all 50 states. If the companies prevail, it would significantly limit the ability of state legislatures to intervene in the pharmacy benefit market.